AZNAstraZenecaFinished
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 552 (final count)
- Started
- Sep 17, 2019
- Main results expected
- Nov 4, 2025
- Fully finished
- Nov 4, 2025
- Results posted
- Sep 1, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs)
Measured over: Up to safety follow-up period (about 30 days from last dose) (approximately 74 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04008706 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC